source
- AstraZeneca’s ATTR-CM Silencer Trial Fails to Show Benefit Over Existing Stabilizer TherapyAstraZeneca announced that its Phase 3 trial of a silencer drug for transthyretin amyloid cardiomyopathy (ATTR-CM) did not meet its primary endpoints. The study showed no additional clinical benefi…
- Vaccine claims dominate federal autism advisory committee meeting, sidelining research funding planAt a recent meeting of the federal autism advisory committee, members spent most of the time discussing vaccines as a possible trigger for autism. The discussion eclipsed the committee’s intended…